ACADIA PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Total stockholders’ equity, beginning balances | $431,755 | $400,413 |
| Common stock: | ||
| Beginning balance | 16 | 16 |
| Ending balance | 16 | 16 |
| Additional paid-in capital: | ||
| Beginning balance | 2,862,552 | 2,770,923 |
| Issuance of common stock from exercise of stock options and units | 1,043 | 1,466 |
| Stock-based compensation | 14,944 | 14,645 |
| Ending balance | 2,878,539 | 2,787,034 |
| Accumulated deficit: | ||
| Beginning balance | (2,430,837) | (2,369,551) |
| Net income (loss) | 16,555 | (43,021) |
| Ending balance | (2,414,282) | (2,412,572) |
| Other comprehensive (loss) income: | ||
| Beginning balance | 24 | (975) |
| Other comprehensive (loss) income | (253) | 755 |
| Ending balance | (229) | (220) |
| Total stockholders’ equity, ending balances | $464,044 | $374,258 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.